By ThinkSabio #ThinkSabio Latest News
AIM – AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerCompany remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint